Introduction
============

The role of pharmacokinetic (PK) and pharmacodynamic (PD) modeling and simulation is expanding in almost all drug development processes, from non-clinical to different phases of clinical trials.\[[@B1]\] The number of regulatory decisions, including new drug approval and labeling, that were effected by pharmacometric analysis increased from 45 submissions between 2000 and 2004 to 87 submissions between 2007 and 2008.\[[@B2][@B3]\] The population approach or pharmacometric analysis based on computational methods is being applied to bridging studies, proof of concept studies for go/no-go decision, simulation for dose selection or study design, and extension to other indications (drug repositioning), among many others.\[[@B1]\] PK/PD modeling and simulation is also used for individualized pharmacotherapy based on relevant demographic factors including race, age, sex, weight, height and genotype.\[[@B4][@B5]\]

Pharmacometric analysis usually relies on non-linear mixed effect models to explain and quantify time-varying PK/PD parameters, disease progression, and their relationships based on population data. Pharmacokinetic models describe the change of drug concentration over time and pharmacodynamic models quantify the relationship between concentration and effect. PK/ PD models link PK models to PD models using direct effect models, effect compartment models, or indirect response models.\[[@B6][@B7]\] This mathematical method is also used for constructing disease progression models comprising the natural history of a disease and drug effect.\[[@B8]\] E~max~ models play important roles in describing excitatory or inhibitory exposure-response relationship. Sigmoid E~max~ models, also known as Hill equations, have successfully explained pharmacodynamics of many drugs with Hill coefficients determining sigmoidicity or sensitivity between exposure and response.\[[@B9]\] However, drug exposure often does not cover the higher range of values required to estimate maximum effect (E~max~) since higher concentrations can either result in toxicity or the testing doses in dose escalation study have little information on dose-response surface. This leads to potentially biased or imprecise PD parameter estimates or overly-simplified models such as linear or log-linear models that are not useful for extrapolation.

The purpose of this simulation study is to explore the limitation of the population PK/PD analysis using data from a clinical study and to help to construct an appropriate PK/PD design that enable precise and unbiased estimation of both fixed and random PD parameters in PK/PD analysis under different doses and Hill coefficients.

Methods
=======

PK/PD Simulation and Estimation
-------------------------------

In this simulation study, seven doses of virtual drugs with equal potency and efficacy but different Hill coefficients were used for generality of interpretation and comparison among virtual drugs and for easy application to PK/PD modeling and simulation of various drugs in clinical use or development. The seven doses were 12.5, 25, 50, 100, 200, 400, and 800 mg, where each succeeding dose was double the preceding dose. The Hill coefficients were 0.5, 1, 2, 5 and 10. Single and multiple-dose studies were simulated with each of the doses and Hill coefficients. A total of 70 (=7 x 5 x 2) scenarios each with 100 subjects were simulated and then estimated 100 times using SSE (Stochastic simulation and estimation) of PSN (Perl-speaks-NONMEM, version 3.7.6, <http://psn.sourceforge.net>) and first order conditional estimation with interaction (FOCE-I) method in NONMEM (version 7.2, ICON Development Solutions, Ellicott City, MD, USA). Pharmacokinetic and pharmacodynamic data were simultaneously simulated and estimated using the same model. A one-compartment model with first-order absorption and elimination was used as the PK simulation model. The true values (θ) of the structural PK parameters for k~a~, CL/F and V/ F were: θ~ka~ = 1 hr^-1^, θ~CL/F~ = 5 L/hr, θ~V/F~ = 100 L, where k~a~, CL/F and V/F was absorption rate constant, clearance and volume of distribution, respectively.

$$C = \frac{F \cdot D}{V} \cdot \frac{k_{a}}{\left( {k_{a} - k_{e}} \right)} \cdot \left( e^{- k_{e} \cdot t} - e^{- k_{a} \cdot t} \right)$$ where C is drug concentration, k~e~ is elimination rate constant, obtained by CL over V, F is bioavailability and D is dose, respectively. The approximate values of the T~max~ (the time at which the maximum concentration was observed) for single- and multiple-dose study were 3.15 and 2.78 h, respectively and the half-life was around 13.9 h. The blood sampling time points for dense sampling schedules were 0 (predose), 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 6, 8, 12, 24, and 48 h after drug administration. The samples at 24 and 48 h were not included for multiple-dose scenarios. The PD measurement time points were equal to those of PK.

A sigmoid E~max~ model was used for PD simulation based on an assumption that plasma concentration is directly linked to the drug effects, as below. $$E = E_{0} + \frac{E_{max} \times C^{\gamma}}{EC_{50}^{\gamma} + C^{\gamma}}$$ where E is drug effect. The true values (θ) of PD parameters for baseline (E~0~), efficacy (E~max~), potency (EC~50~) and Hill coefficients (γ) were: θ~E0~ = 1000, θ~Emax~ = 10000, θ~EC50~ = 1000 ng/mL, and θ~γ~ = 0.5, 1, 2, 5 or 10, respectively. The coefficient of variation (CV%) of random effect for inter-individual variability (IIV) and residual variability (RV) were set at 30% for all PK/PD parameters and 20% for PK/PD observations, respectively. An exponential error model for IIV and RV was applied as follows: $$y_{ij} = \hat{y_{ij}} \times exp\left( \varepsilon_{ij} \right)$$ where *θ~i~* is the i^th^ individual PK/PD parameter, *θ* is the population mean value, η*~i~* is an instance of a normally distributed random variable η with mean zero and variance of ω^2^ which represent IIV, *γ~ij~* is the observed concentrations or effect for the i^th^ subjects at time j, is the individual predicted observations for the for the i^th^ subjects at time j, $\hat{y_{ij}}$ and *ɛ~ij~* is an instance of a normally distributed random variable *ɛ* with mean zero and variance of σ^2^ which represents RV.

The simulated effect versus concentration plots were used to explore the relationship between concentration and EC~50~ and whether E~max~ was attained in each study or not. Simulated concentrations were normalized by true EC~50~ (=1000 ng/mL) to identify the generalized exposure-response relationship and then "EC~50~" was used as a unit to express normalized concentra-tions.\[[@B10][@B11]\]

To evaluate the estimation performance for PD parameters at each dosing scenario, the median values and ranges of normalized maximum concentration (C~max~) (normalized by EC~50~) for single-dose study and normalized steady-state minimum concentration (C~min,ss~) and C~max,ss~ for multiple-dose study at each dose level at all values of γ were obtained using individual predicted values, which were calculated from the parameter estimates from 100 simulated subjects and the simulation time points in each scenario.

To evaluate the estimation performance for PD parameters at each dose, the following statistics were obtained using individual predicted values.

1\) Median values and range of normalized maximum concentration (C~max~) (normalization using EC~50~) for single-dose studies

2\) Normalized steady-state minimum concentration and C~max,ss~ for multiple-dose studies at each dose level at all values of gamma.

Individual predicted values were calculated from the parameter estimates from 100 simulated subjects and simulated time points in each scenario.

Bias and Precision of Parameter Estimates
-----------------------------------------

The bias and precision of the parameter estimates in each scenario were assessed using relative bias and relative root mean square error (RMSE) (instead of bias and RMSE) to compare estimation performance between parameters with different scales.

$$relative bias = 100\%\frac{1}{N}{\sum\limits_{i}^{}\frac{P_{est} - P_{sim}}{P_{sim}}}$$ $$relative RMSE = 100\%\sqrt{\frac{1}{N}{\sum\limits_{i}^{}\frac{\left( P_{est} - P_{sim} \right)^{2}}{P_{sim}^{2}}}}$$ where P~est~ is the fixed or random effect parameter estimate and P~sim~ is the true fixed and or random effect parameters (θ, ω^2^, σ^2^) value used for each simulation. The criteria for accuracy and precision were less than or equal to 15% and 35%, respectively. \[[@B10][@B11][@B12]\]

Results
=======

Eight scenarios out of total seventy scenarios failed stochastic simulation and estimation (SSE), in spite of numerous attempts. The failed scenarios were: four scenarios of 12.5 and 25 mg at high Hill coefficients (γ = 5, 10) in single-dose study and four scenarios of 100, 200, 400 and 800 mg at low Hill coefficients (γ = 0.5) in multiple-dose study. Among the remaining sixty two scenarios which were successful, one scenario in single-dose studies had 1 failure and eight scenarios in multiple-dose studies had 1 to 3 failure(s) during 100 simulations and estimations for each scenario.

PK simulation and estimation
----------------------------

For the single-dose studies, all the PK parameters (θ and ω^2^) for k~a~, CL/F and V/F were unbiased and precise ([Fig. 1a](#F1){ref-type="fig"}), while *ω~ka~*^2^ was considerably biased and imprecise for the multiple-dose studies ([Fig. 1b](#F1){ref-type="fig"}). The CL/F was estimated at best and V/ F was the next in the multiple-dose scenarios ([Fig. 1b](#F1){ref-type="fig"}). The relative bias and RMSE of σ^2^ for the PK observations were less than 0.8% and 5% for single-dose study and 1.4% and 5.1% for multiple-dose study, respectively.

The median ratios of the individual predicted C~max~ and C~max,ss~ to EC~50~ represented, respectively, near two-fold increases from 0.11 to 6.8 EC~50~ units for the single-dose studies and from 0.25 to 16 EC~50~ units for the multiple-dose studies with the increase in doses. The median ratio of the individual predicted C~min,ss~ to EC~50~ for the multiple-dose studies also increased to double from 0.16 to 10 EC~50~ units ([Table 1](#T1){ref-type="table"}).

PD simulation and estimation
----------------------------

In single-dose studies, E~max~ was not attained at γ of 0.5 and 1, while it was attained at higher doses with γ of 2, 5 and 10. In case of multiple-dose studies, only a small part of a full sigmoid E~max~ curve was obtainable ([Fig. 2](#F2){ref-type="fig"}).

For the single-dose scenarios ([Table 2](#T2){ref-type="table"}, [Fig. 3](#F3){ref-type="fig"}), estimated θ~Emax~ and ω~Emax~^2^ were mostly biased at lower doses, while most of them were unbiased and precise when the doses and the C~max~ were, respectively, more than or equal to 100 mg and 0.42 EC~50~ units, except for the biased ω~Emax~^2^ at 100 mg doses (C~max~ = 0.42 EC~50~ units) with γ of 5 and 10 and the imprecise ω~Emax~^2^ at 100 mg doses (C~max~ = 0.42 EC~50~ units) with γ of 2, 5, and 10. θ~EC50~ and ω~EC50~^2^ were reliably estimated at more than or equal to 100 mg doses with γ of 2 and 5 except the imprecise ω~EC50~^2^ at 100 mg dose with γ of 2. The scenarios with γ of 0.5 and 1 resulted in poor estimates of EC~50~ in most doses, while estimates of θ~EC50~ were reliable at more than or equal to 200 mg doses or C~max~ of 0.85 EC~50~ units with γ of 1. With regard to E~0~, the parameter estimates from all single-dose scenarios were precisely estimated with little bias. Parameter estimates of θγ were mostly accurate and precise except for those at 12.5 mg dose (C~max~=0.11 EC~50~ units) with γ of 2 and 800 mg dose (C~max~=6.8 EC~50~ units) with γ of 10, whereas the parameter estimates of ωγ^2^ were reliably estimated only when the doses were 50 mg (C~max~=0.21 EC~50~ units) with γ of 0.5 and 1 or 100 (C~max~=0.85 EC~50~ units) and 200 mg (C~max~= 1.7 EC~50~ units) with all γ except for 100 mg dose (C~max~=0.85 EC~50~ units) with γ of 0.5 and 200 mg (C~max~= 1.7 EC~50~ units) dose with γ of 10. The relative bias and RMSE of σ^2^ for the PD observations were less than 0.9% and 5% for single-dose study, respectively.

For the multiple-dose scenarios ([Table 3](#T3){ref-type="table"}, [Supplementary Fig. 1](#S1){ref-type="supplementary-material"}), it was very difficult to estimate accurate and precise PD parameters. The estimates of θ~Emax~ and ω~Emax~^2^ met the acceptance criteria of bias and precision when the doses were within the range of 50 (C~min~=0.63 and C~max~=0.99 EC~50~ units) and 200 mg (C~min~=2.5 and C~max~=3.9 EC~50~ units) and γ was either 5 or 10. This was not true, however, for 50 mg dose (C~min~=0.63 and C~max~=0.99 EC~50~ units) with γ of 5 and 200 mg dose (C~min~=2.5 and C~max~=3.9 EC~50~ units) with γ of either 5 or 10. Estimates corresponding to these doses resulted in high imprecision. With regard to the estimates of θ~EC50~ and ω~EC50~^2^, the results from designs at 100 mg dose 50 (C~min~=1.3 and C~max~=2.0 EC~50~ units) with γ of 5 and 50 mg dose (C~min~=0.63 and C~max~=0.99 EC~50~ units) with γ of 10 were reliable. Contrary to the results of single-dose studies, the performance of estimating E~0~ represented considerably poor accuracy and precision. θ~E0~ and ω~E0~^2^ were estimated with accuracy and precision, when the doses were in the range of 12.5 and 50 with γ of 5 and 10, except for the imprecise ω~E0~^2^ at 50 mg dose (C~min~=0.63 and C~max~=0.99 EC~50~ units) with γ of 5. Some θ~γ~ were estimated with accuracy and precision, while most ω~γ~^2^ were unreliable. The relative bias and RMSE of σ^2^ for the PD observations were less than 0.9% and 5.1% for multiple-dose study, respectively.

Discussion
==========

This simulation study assumes a typical human pharmacology study design where plasma concentration and effect are frequently measured in order to characterize PK and/or PD. Dense sampling strategies are used in all phases of clinical trials for changing dose, indication, or target population as well as phase 1 clinical trials in new drug development, and pharmacometric analyses are frequently done for these studies. However, not all analyses are successful and the quality of population approach depends on the quality of study design as well as the quantity of data. Therefore, this study aims to specifically investigate the estimation performance of PD parameters based on different data properties given the same quantity of data. In case of sparse sampling, it is natural that parameters are poorly estimated.

Ette et al. suggested a data supplementation (PK/PD knowledge creation or discovery) method to characterize an unknown target region of the response surface, which is very useful in finding appropriate new doses in a completed clinical study with limited information on exposure-response relationship.\[[@B13]\] Dutta et al. found that E~max~, EC~50~, and γ of sigmoid E~max~ model were poorly estimated if the maximum concentration was not attained up to 95% of E~max~ applying clinical data simulation. Seven escalating C~max~ levels with five different Hill coefficients (γ=0.2, 0.5, 1, 2 or 5) were used in simulations. The number of blood samples was ten in each scenario. However, the concentrations were derived from sigmoid E~max~ curve and pharmacokinetics was not considered.\[[@B14]\] The parameter estimation of sigmoid E~max~ model is an important part in dose-finding study. Dragalin et al. found that the adaptive designs with the selected dose applying Fisher information matrix were superior in finding target dose compared to the common designs with the doses allocated by equal interval.\[[@B15]\] Wang et al. also compared the performance of the adaptive design to the uniform design.\[[@B16]\] The purpose of these two studies was to show the performance of adaptive optimal designs for dose-finding studies, (corresponding to phase 2 clinical studies) and pharmacokinetics was not considered. On the other hand, the next two studies used pharmacokinetic sampling designs to investigate pharmacodynamic parameter estimation, as is done in this study. Girgis et al.\[[@B10]\] found that the accuracy and precision of the PD parameter estimates got worse as the number of subjects decreased from 100 to 25 with sparse sampling design. Pai et al.\[[@B11]\] performed a series of studies that evaluated the effect of octreotide on the insulin-like growth factor-1and the effect of remifentanil on electroencephalogram, which were successfully described using sigmoid E~max~ model with moderate sigmoidicity (γ=2.51) and simple E~max~ model (γ=1), respectively, while the previous study of theophylline-induced eosinopenia was described using a model of high sigmoidicity. The latter study investigated the change in bias and precision in relation to Hill coefficient using 100 subjects in each scenario and 4 to 5 sparse samplings based on the former study and found that the plasma concentration of two to three times EC~50~ was needed to get reliable parameter estimates if the drug exhibited high Hill coefficient, and that the plasma sampling near EC~50~ was important with simple E~max~ model. In the two studies, all the estimated ω~γ~^2^ were biased and imprecise, whereas ω~γ~^2^ of 10 scenarios, including doses of 50 (C~max~=0.42 EC~50~ units) and 100 mg (C~max~=0.85 EC~50~ units) with γ of 0.5, 50 to 200 mg with γ of 1, 100 and 200 mg with γ of 2 or 5 and 200 mg (C~max~=1.7 EC~50~ units) with γ of 10, among 31 single-dose scenarios were accurately and precisely estimated in this study with dense sampling design.

In this study, the number of subjects was set to 100 in each scenario and dense sampling design was adopted based on the results of the previous studies to investigate the estimation performance with regard to differing concentration and Hill coefficients while fixing the number of subjects and sampling points. Using virtual drugs with different Hill coefficients and ratios of concentration to EC~50~ would facilitate general interpretation and easy application to the real drugs.

For the single-dose studies, the SSE processes failed when the doses were 12.5 (C~max~=0.11 EC~50~ units) and 50 mg (C~max~=0.42 EC~50~ units) and γ was either 5 or 10, because the simulated concentrations were located at lower flat area of the sigmoid E~max~ curve ([Fig. 2](#F2){ref-type="fig"}). The accuracy and precision of θ~Emax~ and ω~Emax~^2^ were getting better with the increase in dose, regardless of γ, while those of θ~EC50~ and ω~EC50~^2^ gradually improved with increase in both dose and γ ([Fig. 3](#F3){ref-type="fig"}). In single-dose studies, since the baseline of effects before dosing was measurable, all the θ~E0~ and ω~E0~^2^ were estimated with accuracy and precision. The estimated θ~γ~ showed various trends at different values of γ. The absolute values of relative bias for θ~γ~ were represented by a U-shaped curve when γ was 0.5, 5 or 10, while they grew with increase in dose when γ was either 1 or 2 ([Fig. 3](#F3){ref-type="fig"}). The relative RMSE for θ~γ~ and the relative bias and relative RMSE for ω~γ~^2^ also represented U-shape trends regardless of γ ([Fig. 3](#F3){ref-type="fig"}), because the bottom area of the effects were measured with lower doses and the ceiling area were measured with higher doses. Sampling enough concentrations corresponding to the whole range of the effect curve must be crucial to estimate reliable θ~γ~ and ω~γ~^2^ ([Fig. 2](#F2){ref-type="fig"}).

The estimation capabilities of the PD parameters except for θ~E0~ and ω~E0~^2^ with different Hill coefficients (γ) in single-dose scenarios are as follows ([Fig. 3](#F3){ref-type="fig"}). For the γ of 0.5, all the estimates of θ~Emax~ and ω~Emax~^2^ were reliable when the dose was at least 50 mg or C~max~ was more than 0.42 EC~50~ units. The estimates of θ~γ~ and ω~γ~^2^ were accurate and precise only under doses of 50 (C~max~=0.42 EC~50~ units) and 100 mg (C~max~=0.84 EC~50~ units). However, θ~EC50~ and ω~EC50~^2^ were poorly estimated in all dosing scenarios. The reason seemed that the range of concentration-effect relationships was not enough to describe whole shape of sigmoid E~max~ model as shown in the multiple-dose scenarios. The effect-concentration profiles obtained from various doses seem to be needed to estimate accurate and precise θ~EC50~ and ω~EC50~^2^. For the γ of 1, all the estimates of θ~Emax~ and ω~Emax~^2^ were reliable when the dose was at least 100 mg or C~max~ was more than 0.85 EC~50~ units. θ~EC50~ was accurately and precisely estimated when the dose was at least 100 mg (C~max~=0.84 EC~50~ units), while ω~EC50~^2^ was hardly estimated, as shown in a previous study.\[[@B11]\] The estimates of θ~γ~ and ω~γ~^2^ were accurate and precise when the doses were within the range of 50 to 400 mg (C~max~=0.42 to 3.4 EC~50~ units). This was not true, however, for 800 mg dose (C~max~=6.8 EC~50~ units) owing to lack of information on sigmoidicity in concentration-effect relationship. For the γ of 2 to 10, all the parameter estimates for E~max~ and EC~50~ met the acceptance criteria of bias and precision when the doses were more than or equal to 200 mg (C~max~=1.7 EC~50~ units). This is a relatively smaller value than the result form a study which reported that the 2 to 3 EC~50~ region is needed to get an unbiased and precise estimate of ω~Emax~^2^, when γ was 6.22 and blood sampling was sparse.\[[@B10]\] A dense sampling design is recommended to get a precise ωE~C502~, because it was impossible with sparse sampling design.\[[@B11]\]

Both the θ~γ~ and ω~γ~^2^ met the criteria for accuracy and precision at 100 (C~max~=0.84 EC~50~ units) and 200 mg (C~max~=1.7 EC~50~ units) with γ of 2, 100 to 400 mg (C~max~=0.84 to 3.4 EC~50~ units) with γ of 5, and 200 mg (C~max~=1.7 EC~50~ units) with γ of 10. On the other hand, Girgis et al. found that all θ~γ~ and ω~γ~^2^ were biased and imprecise when the Hill coefficient was high (γ=6.22), 4 to 5 blood samples were gathered\[[@B10]\] and Pai et al. also reported similar results from spare sampling design, when γ were 1 or 2.51.\[[@B11]\] These results suggest that dense sampling design may be essential to get accurate and precise estimates of θ~γ~ and ω~γ~^2^.

These results can be applied to clinical trials and PK/PD modeling of resultant data. When a clinical study is performed to evaluate the PK/PD of an investigational product with Hill coefficients of 2, an investigator can use 200 mg (C~max~=1.7 EC~50~ units) to get the best results of parameter estimation or 100 mg (C~max~=0.84 EC~50~ units) to get useful parameter estimates with less toxicity. On the other hand, an investigator can interpret the reliability of the results from PK/PD modeling based on the results of this study.

For the multiple-dose studies ([Table 3](#T3){ref-type="table"}, [Supplementary Fig. 1](#S1){ref-type="supplementary-material"}), the parameter estimation performance was not good. In this simulation setting, the accumulation index was 2.22 with the half-life of 14 hours and 12 hour dosing interval. The concentration-effect profile obtained from this setting could not include the whole range of effects and resulted in poor performance. If the dosing interval was longer than 12 hours or the drug had lower accumulation rate than 2.22, wider range of concentration-time profiles could be gathered. The worse performance of PK parameter estimation in multiple-dose settings than in single-dose settings might play a role in the poor estimates of PD parameter. On the other hand, errors in PD parameter estimates might have negatively affected PK parameter estimation, and this is hinted from different levels of bias and precision with different combinations Hill coefficients and doses, although the Hill coefficient had no relation to pharmacokinetics. If PK/PD modeling is performed with data from multiple-dose studies, the sampled concentrations may include at least 0.63 EC~50~ and at most 3.9 EC~50~ corresponding to the doses of 50 to 200 mg in this study.

This study has some limitations. Since the PK profiles were simulated under the assumption of dose proportionality, the relationship between dose and EC~50~ units might change if investigational drugs have nonlinear PK properties. However, the exposure-response relationship can be easily understood and applied, if concentrations are normalized by EC~50~. Another limitation is that only one dosing interval was used for simulation in the multiple-dose scenarios. Since a different dosing interval may yield a different steady-state fluctuation, the parameter estimation performance can be better or worse than this study according to the dosing interval. A further limitation stems from the limited range of variability parameters of this study. Since all CV% of IIV and RV were set at moderate values of 30% and 20%, respectively, prediction of exposure-response relationship of a drug with larger variability might show deviations from our findings. Simultaneous modeling of PK/PD is one of the causes of poor IIV estimation, and certain types of sequential approaches may result in better performance.\[[@B17]\]

This simulation study demonstrated the effect of the relative range of sampled concentrations to EC~50~ and sigmoidicity (or sensitivity) between exposure and response on the parameter estimation performance using dense sampling design. In single-dose studies, most PD parameters of sigmoid E~max~ model were accurately and precisely estimated when the C~max~ was more than 0.85 EC~50~ units, except for typical value and IIV of EC~50~ which were poorly estimated at low Hill coefficients (γ=0.5 and 1) regardless of doses. The PK/PD modeling results using only steady-state data may be carefully interpreted. This study can be useful in designing a clinical study to evaluate PK/PD relationship for new drug development or drug repositioning.
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###### Supplementary Figure 1

Relative bias (a) and relative root mean square error (b) of pharmacodynamic parameters estimates for the multiple-dose scenarios.

![Relative bias (upper) and relative root mean square error (lower) of pharmacokinetic parameters estimates for the single-dose scenarios (a) and the multiple-dose scenarios (b).](tcp-25-74-g001){#F1}

![Effects versus concentrations/EC50 plots relevant to each simulation scenario for the single-dose scenarios (a) and the multiple-dose scenarios (b).](tcp-25-74-g002){#F2}

![Relative bias (a) and relative root mean square error (b) of pharmacodynamic parameters estimates for the single-dose scenarios.](tcp-25-74-g003){#F3}

###### Normalized C~min~ and C~max~ by EC50 at each dose scenario

![](tcp-25-74-i001)

  Dose (mg)   Single dose   Multiple Doses                                 
  ----------- ------------- ---------------- ------ --------------- ------ ---------------
  12.5        0.11          (0.10 - 0.11)    0.16   (0.14 - 0.18)   0.25   (0.23 - 0.26)
  25          0.21          (0.20 - 0.23)    0.32   (0.28 - 0.35)   0.49   (0.46 - 0.53)
  50          0.42          (0.39 - 0.45)    0.63   (0.57 - 0.71)   0.99   (0.92 - 1.1)
  100         0.85          (0.78 - 0.91)    1.3    (1.1 - 1.4)     2.0    (1.9 - 2.1)
  200         1.7           (1.5 - 1.8)      2.5    (2.3 - 2.8)     3.9    (3.7 - 4.2)
  400         3.4           (3.1 - 3.6)      5.1    (4.6 - 5.6)     7.9    (7.4 - 8.4)
  800         6.8           (6.3 - 7.2)      10     (9.1 - 11)      16     (15 - 17)

^\*^, the median values and ranges of normalized maximum concentration for single-dose study, ^†^, the median values and ranges of normalized minimum concentration for multiple-dose study, ^‡^, the median values and ranges of normalized maximum concentration for multiple-dose study.

###### Bias and Precision for PD parameters in Single-Dose Scenarios (All values are rounded off to have 3 figures to allow for better readability

![](tcp-25-74-i002)

  Gamma           relative BIAS (Accuracy: ≤15%, shaded)   relative RMSE (Precision: ≤35%, shaded)                                                                                                      
  ------- ------- ---------------------------------------- ----------------------------------------- ------- ------- ------- -------- -------- ------- ------ ------ ------ ------ ------ ------ ------ ------
  0.5     12.5    26.5                                     −23.0                                     316     31.9    −4.20   −1.60    −4.00    −20.0   62.6   49.3   1140   225    5.78   21.7   8.56   35.3
  25      13.8    −14.0                                    113                                       8.67    −4.30   −1.60   −2.20    −16.0    36.7    35.9   410    209    5.82   22.1   7.83   31.9   
  50      7.02    −6.50                                    39.8                                      −21.0   −4.30   −1.40   −0.50    −13.0    19.9    24.3   94.0   166    5.85   22.3   8.05   29.0   
  100     4.67    −4.50                                    29.3                                      −19.0   −4.40   −1.10   0.94     −13.0    16.7    21.3   77.5   166    5.87   22.4   9.86   30.8   
  200     2.55    −3.80                                    26.1                                      −6.10   −4.40   −0.90   2.97     −18.0    15.8    17.7   92.1   165    5.89   22.5   13.2   37.5   
  400     2.18    −2.70                                    36.7                                      −6.50   −4.40   −0.70   3.86     −26.0    16.6    15.6   141    167    5.91   22.4   16.2   49.2   
  800     0.74    −2.80                                    48.5                                      30.0    −4.50   −0.50   5.78     −34.0    16.2    16.6   287    287    5.92   22.5   19.4   68.4   
  1       12.5    120                                      −68.0                                     346     85.8    −2.20   −0.50    −8.40    −28.0   398    84.1   1520   241    4.09   17.1   10.9   46.9
  25      30.3    −33.0                                    63.9                                      39.3    −2.50   −1.40   −5.60    −19.0    69.6    64.1   159    136    4.30   18.2   7.73   35.0   
  50      10.9    −3.30                                    21.0                                      −5.50   −2.90   −1.70   −3.90    −13.0    22.4    43.6   38.8   89.0   4.60   19.7   6.42   26.3   
  100     7.80    6.88                                     15.7                                      −32.0   −3.30   −1.00   −3.70    −10.0    15.0    30.1   28.4   75.3   4.88   20.6   6.41   22.6   
  200     2.73    3.55                                     5.60                                      −22.0   −3.50   −0.10   −2.10    −12.0    8.43    21.0   17.8   62.5   5.04   21.4   5.77   25.1   
  400     0.16    1.37                                     0.07                                      −13.0   −3.60   0.43    −0.20    −16.0    5.47    18.7   11.5   62.0   5.11   21.9   6.14   33.2   
  800     −0.40   1.89                                     −1.20                                     −25.0   −3.70   0.81    0.00     −23.0    4.58    18.0   9.61   72.9   5.16   22.2   8.00   55.0   
  2       12.5    1420                                     48.0                                      1320    39.4    −1.00   1.03     −17.0    −55.0   6820   328    6170   258    3.59   17.1   23.3   71.5
  25      824     −50.0                                    390                                       1.08    −1.20   1.13    −10.00   −42.0    3290    153    1650   111    3.56   18.0   14.6   52.9   
  50      31.8    −33.0                                    25.6                                      8.20    −1.60   0.10    −6.20    −22.0    54.9    83.9   40.4   50.6   3.78   18.0   8.54   34.1   
  100     4.57    3.52                                     5.79                                      −7.40   −2.60   0.25    −4.30    −7.50    12.7    47.8   12.2   37.5   4.35   19.1   6.45   22.2   
  200     −1.30   0.16                                     −0.90                                     −9.00   −3.20   −0.20   −1.90    −5.00    4.89    19.4   5.33   29.0   4.80   20.8   4.97   24.7   
  400     −1.10   −1.20                                    −0.80                                     −11.0   −3.80   0.34    −1.30    −6.50    3.68    14.9   4.60   27.2   5.23   21.9   5.66   37.1   
  800     −0.80   −0.80                                    0.36                                      −8.80   −4.20   1.50    −1.80    −24.0    3.17    14.3   4.45   30.9   5.53   22.9   6.85   49.0   
  5       50      800                                      99                                        23.0    −13.0   −0.20   1.69     −10.00   −35.0   4400   492    79.5   53.7   2.68   15.2   14.4   56.7
  100     2.66    −22.0                                    1.56                                      2.56    −0.70   0.56    −4.50    −8.60    11.9    49.1   5.81   20.8   2.85   15.0   7.47   28.6   
  200     −1.40   −3.80                                    −0.20                                     −0.20   −1.50   0.76    −2.90    −8.40    4.02    21.5   3.11   17.0   3.30   16.1   5.21   28.4   
  400     −0.50   −0.80                                    1.12                                      −2.00   −2.40   1.33    −5.40    −8.90    3.01    15.3   3.43   18.9   3.85   17.4   7.09   35.6   
  800     0.00    −1.80                                    2.71                                      −2.90   −3.40   3.02    −13.0    −17.0    2.81    14.1   4.88   21.1   4.68   18.6   14.7   67.0   
  10      50      302                                      175                                       2.60    −24.0   −0.30   −0.20    −11.0    −13.0   1600   792    29.4   49.5   2.89   14.4   20.5   118
  100     −0.30   −15.0                                    −0.90                                     −9.00   −0.30   −0.10   −5.60    −9.00    6.50    35.5   3.99   20.5   3.11   15.0   7.48   35.9   
  200     −0.60   −3.30                                    0.00                                      −1.60   −1.20   0.00    −5.20    −1.50    3.25    17.8   3.63   16.1   3.31   15.9   6.87   28.2   
  400     −0.20   −2.10                                    1.03                                      −4.70   −2.10   1.78    −13.0    11.0     3.18    14.4   3.79   16.3   3.92   19.9   14.1   62.3   
  800     0.05    −2.80                                    2.04                                      −5.90   −3.60   −1.20   −28.0    61.2     3.20    14.4   5.58   25.4   5.00   18.9   28.6   132    

###### Bias and Precision for PD parameters in Multiple-Dose Scenarios (All values are rounded off to have 3 figures to allow for better readability.)

![](tcp-25-74-i003)

  Gamma           relative BIAS (Accuracy: ≤15%, shaded)   relative RMSE (Precision: ≤35%, shaded)                                                                                                                   
  ------- ------- ---------------------------------------- ----------------------------------------- -------- ------- -------- ------- ------- -------- -------- -------- -------- ------ -------- -------- -------- --------
  0.5     12.5    106                                      −1.90                                     1.E+03   144     −10.0    42700   55.3    −19.0    833      83.5     3.E+03   607    137      4.E+05   157      126
  25      134     14.9                                     718                                       88.0     19.2    2.E+06   85.4    −29.0   1.E+03   102      4.E+03   540      192    2.E+07   177      136      
  50      13.7    25.1                                     644                                       86.6     41.4    −410     91.5    −3500   154      95.0     2.E+03   526      257    1.E+04   165      3.E+04   
  1       12.5    283                                      −40.0                                     1.E+03   22.6    −22.0    −46.0   −13.0   −20.0    2.E+03   79.4     5.E+03   200    40.3     108      26.6     80.4
  25      80.7    −23.0                                    741                                       3.87     −27.0   2.E+04   −6.60   −27.0   178      64.0     4.E+03   143      60.2   1.E+05   32.0     92.6     
  50      16.0    1.54                                     68.2                                      −8.70    −21.0   4.E+04   12.3    −33.0   57.8     49.6     304      150      138    4.E+05   51.0     106      
  100     10.4    14.8                                     0168                                      −7.30    −5.40   4.E+03   17.5    −17.0   63.7     64.1     974      195      210    4.E+04   50.1     174      
  200     9.97    16.9                                     195                                       57.4     −38.0   1.E+03   19.5    18.7    51.4     80.0     1.E+03   426      318    8910     57.1     260      
  400     10.6    25.0                                     780                                       278      −9.00   −60.0    26.0    122     58.3     96.8     4.E+03   1.E+03   453    141      74.4     453      
  800     5.38    60.9                                     1.E+03                                    415      69.9    6700     48.2    349     51.9     204      6.E+03   2.E+03   389    5.E+04   165      1.E+03   
  2       12.5    806                                      −15.0                                     599      −13.0   −3.70    −4.30   −15.0   −44.0    2330     179      1870     135    12.1     46.8     25.9     70.6
  25      127     −24.0                                    107                                       −12.0    −4.80   −16.0    −9.00   −27.0   304      108      295      73.5     14.8   66.1     17.9     64.7     
  50      14.5    5.91                                     18.3                                      −17.0    −6.00   −33.0    −3.50   −29.0   41.2     55.2     54.1     57.4     34.2   128      20.8     68.6     
  100     2.45    3.74                                     3.69                                      −24.0    −11.0   3.E+03   2.48    −42.0   24.2     35.6     29.7     56.3     117    3.E+04   25.1     97.0     
  200     −4.30   17.0                                     15.0                                      −40.0    51.2    1.E+04   9.67    25.8    30.8     68.3     36.8     96.6     268    1.E+05   38.6     243      
  400     −24.0   101                                      84.7                                      −34.0    269     1.E+05   69.5    200     42.2     222      232      203      402    1.E+06   256      777      
  800     −14.0   299                                      1.E+04                                    297      228     83100    77.0    134     49.5     1450     81700    2.E+03   434    8.E+05   230      541      
  5       12.5    881                                      544                                       104      62.2    −1.90    1.63    −5.80   24.7     5.E+03   1690     365      693    5.68     17.6     67.9     284
  25      319     79.6                                     20.7                                      −7.00    −1.00   4.13     −13.0   −59.0   2.E+03   380      59.8     50.5     4.98   20.2     18.8     74.3     
  50      0.57    −5.60                                    0.70                                      −0.80    −1.80   −11.0    −5.30   −30.0   11.2     51.3     6.22     21.1     7.82   39.6     10.8     58.8     
  100     −0.30   0.58                                     2.01                                      −15.0    −6.90   −65.0    −5.40   −14.0   4.87     20.0     5.08     27.1     19.3   82.9     12.3     74.4     
  200     −4.80   8.54                                     9.55                                      −24.0    47.7    −29.0    2.64    15.0    23.1     48.1     19.5     65.7     224    193      51.2     246      
  400     −20.0   96.0                                     654                                       253      254     5940     98.2    174     66.7     284      6420     2.E+03   579    3.E+04   299      790      
  800     −22.0   141                                      3350                                      −42.0    245     68.7     60.8    165     58.9     445      3.E+04   176      593    930      222      804      
  10      12.5    865                                      25.5                                      93.9     −41.0   −1.10    −2.10   94.4    191      4.E+03   646      643      142    4.99     14.5     218      1.E+03
  25      23.1    116                                      2.37                                      −13.0    0.00    −3.00    −19.0   −31.0   90.0     749      16.6     38.9     3.24   16.6     23.4     111      
  50      −1.00   −2.20                                    −0.20                                     −4.20    0.48    −3.50    −7.20   −33.0   7.11     32.6     3.81     20.5     4.43   29.1     9.88     60.4     
  100     −0.10   −2.50                                    3.64                                      −18.0    −1.10   −24.0    −11.0   −15.0   3.85     18.7     5.51     29.1     11.7   59.4     14.0     63.6     
  200     −4.10   6.78                                     5.98                                      −3.90    41.1    −31.0    −3.90   235     15.0     48.4     20.1     134      141    182      36.5     777      
  400     −8.20   132                                      4.E+04                                    7.E+03   259     −24.0    46.1    663     157      645      4.E+05   4.E+04   543    130      161      2.E+03   
  800     −24.0   137                                      217                                       −48.0    263     1820     2.75    42.3    58.6     606      1.E+03   72.8     586    1.E+04   74.7     422      
